ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Michele Musci
Matthias Bauer
Roland Hetzer
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zurbrügg, H. R.
Right arrow Articles by Hetzer, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zurbrügg, H. R.
Right arrow Articles by Hetzer, R.

Ann Thorac Surg 2000;70:1536-1540
© 2000 The Society of Thoracic Surgeons

Original articles: cardiovascular

The biocompound method in coronary artery bypass operations: surgical technique and 3-year patency

Heinz Robert Zurbrügg, MDa, Friedrich Knollmann, MDa, Michele Musci, MDa, Markus Wieda, Matthias Bauer, MDa, Tito Chavez, MDa, Andreas Krukenberg, MDa, Roland Hetzer, MD, PhDa

a Deutsches Herzzentrum Berlin, Berlin, Germany

Address reprint requests to Dr Zurbrügg, Deutsches Herzzentrum Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
e-mail: zurbruegg{at}dhzb.de

Background. Complete arterial revascularization may be unsafe in patients with a high operative risk. In patients with varicose ectatic veins, the biocompound technique, which uses unsuitable autologous veins, enables the surgeon to influence the bypass graft wall stress levels and diameter. This report summarizes the 3-year patency of 53 patients, the survival rate of 200 patients, and operative technical considerations.

Methods. Biocompound grafts were used for aortocoronary bypass in 200 patients who were considered inappropriate subjects for complete arterial revascularization and who had unsuitable saphenous veins.

Results. The mortality rate (30 days) of 200 patients was 3.5%. The 3-year survival rate was 88.5%. The patency rate of the left internal thoracic artery (LITA) after 3 years was 97.3%, of the native vein was 68.7%, and of the biocompound graft was 68.3%. The LITA showed a superior patency rate (p = < 0.05).

Conclusions. The LITA is the first choice in coronary bypass operation. The biocompound technique is a reliable method to achieve complete revascularization in patients with a lack of suitable saphenous veins.




This article has been cited by other articles:


Home page
 FASEB J.Home page
K. Laflamme, C. J. Roberge, G. Grenier, M. Remy-Zolghadri, S. Pouliot, K. Baker, R. Labbe, P. D'Orleans-Juste, F. A. Auger, and L. Germain
Adventitia contribution in vascular tone: insights from adventitia-derived cells in a tissue-engineered human blood vessel
FASEB J, June 1, 2006; 20(8): 1245 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 VASC ENDOVASCULAR SURGHome page
C. Recek
Saphenofemoral Junction Ligation Supplemented by Postoperative Sclerotherapy: A Review of Long-Term Clinical and Hemodynamic Results
Vascular and Endovascular Surgery, November 1, 2004; 38(6): 533 - 540.
[Abstract] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
W. Stooker, H.W.M. Niessen, W.R. Wildevuur, V.W.M. van Hinsbergh, J. Fritz, E.K. Jansen, Ch.R.H. Wildevuur, and L. Eijsman
Perivenous application of fibrin glue reduces early injury to the human saphenous vein graft wall in an ex vivo model
Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 212 - 217.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2000 by The Society of Thoracic Surgeons.